Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.
Department of Vascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. s.i.vanleuven@amc.uva.nl
Sander I
SI
van Leuven
Yanice V
YV
Mendez-Fernandez
Erik S
ES
Stroes
Paul P
PP
Tak
Amy S
AS
Major
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D051379:Mice
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors